1. Introduction
===============

Acute upper respiratory tract infection (URTI) is the most widespread type of acute infection. Two common causes of URTI are human rhinovirus (hRV) and human metapneumovirus (hMPV), accounting for approximately 48% and 10% of URTIs, respectively ([@bib17], [@bib8]). However, hRV and hMPV can also cause lower respiratory tract (LRT) symptoms such as severe bronchiolitis and pneumonia ([@bib20], [@bib5]).

Detection of both viruses is non-optimal by conventional cell culture and the slow-growth of hMPV was one of the reasons for the late discovery of the virus ([@bib14]). Accurate diagnosis of hRV and hMPV requires molecular methods ([@bib1], [@bib20], [@bib3], [@bib4], [@bib15], [@bib18], [@bib21]). Most of the PCRs described for detection of hMPV and hRV are designed to identify the virus with individual PCRs and are either time consuming as they require post PCR analysis or costly as they require two PCR reactions. One of the benefits of real-time PCR is that amplifications can be multiplexed as probes carrying different fluorophores enable differentiation of the amplified products. This also results in savings of time and money. To date no hMPV multiplex applications have been described.

When using PCR as a diagnostic tool, adequate controls should be included to ensure the integrity of the assay. Monitoring RNA isolation and inhibition of the samples can be achieved by spiking the clinical samples with a known amount of a non-human virus ([@bib12]). This internal control is co-extracted and co-amplified in the reaction and results in a fixed cycle threshold (Ct) value in the real-time PCR for a properly isolated and un-inhibited sample. Obviously the spike reaction has been designed in a way that the other PCRs in the multiplex are not affected. In this way negative results are generated with greater confidence.

The purpose of this study was to develop a multiplex real-time PCR for hMPV, hRV with an internal control, which would provide a rapid, sensitive and specific test with sufficient controls for use in the diagnosis of these viruses. Additionally, the prevalence and clinical significance of these viruses was assessed in 358 respiratory samples taken from 239 patients in December 2001 until December 2002.

2. Materials and methods
========================

2.1. Viruses and viral stocks
-----------------------------

hMPV (Ned/00/01) was cultured on rhesus monkey kidney (LLC-MK2) cells and hRV (hRV type 16 -- laboratory isolate) in human epidermoid larynx carcinoma (HEL) cells. Ten-fold dilution series of the virus stocks were cultured in duplicate on 24-well plates, centrifuged for 30 min at 1500 ×  *g* and incubated in CO~2~ (hMPV at 36 °C and hRV 32 °C) for 10 days. The 50% tissue culture infective dose (TCID~50~) with the presence of the cytopathic effect (CPE) was determined and aliquots were stored for PCR optimisation. Some additional subtypes of hRV were cultured as well: hRV1a, hRV1b, hRV15, hRV39, hRV51, hRV59, hRV85, hRV86, hRV91.

Equine arteritis virus (EAV) (Bucyrus strain) was used as the internal control and was cultured in baby hamster kidney cells (BHK-21) at 39.5 °C. The stock contained 10^10^ plaque forming units/ml.

2.2. Clinical specimens
-----------------------

The respiratory specimens consisted of all samples that were submitted for conventional routine diagnosis of respiratory viruses from December 2001 to December 2002. In total 358 samples were collected from 239 patients of whom 146 were immunocompromised and 93 immunocompetent. The specimens collected were 178 nasal swabs, 146 throat washes, 21 bronchial alveolar lavages (BALs) and 13 sputa. Aliquots of all specimens were stored at −80 °C prior to nucleic acid isolation and PCR.

2.3. Respiratory viral culture
------------------------------

Cultures were performed by inoculating HEp-2, epidermoid larynx carcinoma (HEL) and LLC-MK2 cells with each of the clinical samples. Approximately 100 μl of the sample was inoculated onto the cell-lines in shell vials. Shell vials were centrifuged at 1500 ×  *g* for 30 min. One HEL shell vial was incubated at 32 °C and the other at 37 °C. The LLC-MK2 and HEp-2 were incubated at 35 °C. All shell vials were incubated for 14 days and examined daily for cytopathic effect. Immunofluorescence with commercial monoclonal antibodies for influenza A, influenza B, respiratory syncytial virus (RSV), parainfluenza virus (PIV) 1--3 and adenoviruses confirmed positive cytopathic effects. (Dako Diagnostics, Glostrup, Denmark). Rhinoviruses were distinguished from enteroviruses by means of acid-lability testing.

2.4. Specificity of multiplex PCR
---------------------------------

A panel of respiratory viruses and bacteria commonly found in the respiratory tract was used to determine the specificity of the multiplex RNA-PCR. Nucleic acids were extracted from influenza A, influenza B, RSV, PIV1--4, adenovirus (type 5), coronavirus (229E), echovirus 7, coxsackievirus B4, human parechovirus type 1 (formerly echovirus 22), mumps virus, measles virus, *Bordetella bronchiseptica*; *Bordetella parapertussis*; *Bordetella pertussis*; *Burkholderia cepacia*; *Chlamydia pneumoniae*; *Haemophilus influenzae*; *Klebsiella pneumoniae*; *Legionella pneumophila*; *Mycoplasma pneumoniae*; *Pseudomonas aeruginosa*; *Staphylococcus aureus*; and *Streptococcus pneumoniae* and tested by the multiplex PCR.

2.5. RNA isolation
------------------

For the development and optimisation of the multiplex RNA-PCR, RNA of hMPV and hRV positive material was extracted from cell culture supernatants by using the QiaAmp^®^ Viral RNA Mini kit (Qiagen, Hilden, Germany). The MagNA Pure LC System (Roche Applied Science, Penzberg, Germany) was used to extract the nucleic acids from clinical specimens to assess automated extraction for routine diagnosis.

2.6. Primers and probes
-----------------------

The primers and probe sequences were selected from the L Gene sequence of hMPV ([@bib20]), the 5′ non-coding region of hRV, and the replicase ORF1a polyprotein gene of EAV. The first step in the design of the PCR was to perform an alignment to ensure selection of conserved regions within a target. The primer and probe interactions were checked using Beacon Designer 2.0 using Accession no [AF371337](AF371337) of hMPV, [D00239](D00239) for hRV and [X53549](X53549) for EAV (Premier Biosoft International, Palo Alto, USA). A BLAST search was performed to check specificity of the sequences of the primers and probes. Primers Taqman and molecular beacons are described in [Table 1](#tbl1){ref-type="table"} . The primers were prepared by Eurogentec (Eurogentec, Seraing, Belgium) and the probes were synthesized by Biolegio (Biolegio, Malden, The Netherlands).Table 1Primers and probes used in the multiplex assayTargetPrimerSequence and labelPCR product size (bp)hMPV342MPVsCATGCCCACTATAAAAGGTCAG170343MPVasCACCCCAGTCTTTCTTGAAA542MPVMBHEXHEX-*GCTGCGG*CATGYCAYTGGTGTGGGATATT*CGCAGC*-BHQ-1  HRV235HRVsGACARGGTGTGAAGSYC142236HRVasCAAAGTAGTYGGTCCCATCC522HRV-TQ-FAMFAM-TCCTCCGGCCCCTGAATG*YGGCTAA*-BHQ-1  EAV417EAVsCATCTCTTGCTTTGCTCCTTAG134418EAVASAGCCGCACCTTCACATTG562EAVMBCY5CY5-*CGCGCT*CGCTGTCAGAACAACATTATTGCCCAC*AGCGCG*-BHQ-2[^1]

2.7. Multiplex real-time RNA PCR
--------------------------------

Before the multiplex PCR was set up, the individual assays were optimised by determining optimum Mg^2+^, annealing temperatures, and primer and probe concentrations. For the multiplex RNA-PCR the Qiagen^®^ one-step RT-PCR kit (Qiagen, Hilden, Germany) was used. The reaction was performed in 50 μl of reaction mixture consisting of 10 μl of 5X Qiagen one-step RT-PCR buffer, 10 mM dNTPs, 4.5 mM MgCl~2~, 0.6 μM of each primer for hMPV, 0.4 μM of each primer for hRV and EAV, 0.34 μM of molecular beacon for hMPV and of Taqman probe for hRV and 0.25 μM of the molecular beacon for EAV. After addition of 5 μl template. The PCR thermal profile consisted of an initial cDNA step of 30 min at 50 °C followed by 15 min at 95 °C and 50 cycles of 30 s at 95 °C, 30 s at 55 °C and 30 s at 72 °C. Amplification, detection and data analysis were performed with an iCycler IQ real-time detection system (BioRad, Veenendaal, The Netherlands).

2.8. Nucleotide sequence analysis of hMPV positive patients
-----------------------------------------------------------

For all hMPV positive patients, the PCR products with a size of approximately 170 bp were subjected to nucleotide sequence analysis to determine the hMPV subtypes. The analysis was carried out on an ABI Prism 310 genetic analyser using the Big Dye terminator kit (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands).

3. Results
==========

3.1. Multiplex RNA-PCR for hMPV, hRV and EAV
--------------------------------------------

The analytical sensitivity of the multiplex PCR was determined at 0.01 TCID~50~ for both hMPV and hRV. The cycle threshold values obtained in the multiplex analyses were compared to the individual PCRs and no difference in sensitivity was achieved as shown in [Table 2](#tbl2){ref-type="table"} .Table 2Comparison of Ct values after amplification of dilution series of titrated virus in mono-specific and multiplex real-time PCRCt value (individual PCR)Ct value (multiplex)Ct value (multiplex with EAV spike)Rhinovirus 100 TCID~50~26.226.526.3 10 TCID~50~29.429.329.7 1 TCID~50~33.133.133.4 0.1 TCID~50~36.536.337.1 0.01 TCID~50~40.240.540.9 0.001 TCID~50~000  Metapneumovirus 100 TCID~50~19.219.119.7 10 TCID~50~23.123.323.5 1 TCID~50~27.327.127.9 0.1 TCID~50~31.231.232.0 0.01 TCID~50~36.438.138.2 0.001 TCID~50~000[^2]

Specificity testing of the multiplex PCR showed that no other respiratory pathogens were amplified in this assay except for enteroviruses. A high titre enterovirus stock of 100 TCID~50~ resulted in weak amplification (Ct 42) in the hRV assay.

When analysing the PCR products of the hMPV individual RNA-PCR on a 2%-agarose gel, non-specific bands were amplified as well as shown in [Fig. 1](#fig1){ref-type="fig"} . Thus, the specificity of the reaction was conferred by hybridisation of the molecular beacon. All PCR-products with an approximate size of 170 bp were analysed by sequence analysis. Samples positive for hMPV in real-time PCR showed a complete match to the sequence of the hMPV isolate with Genbank number [AF371337](AF371337). The non-specific bands, negative by real-time PCR, appeared to be human DNA of a variety of chromosomes after sequencing.Fig. 1PCR products generated by the hMPVprimers on a 2%-agarose gel. *M* = 100 bp ladder. Lane 1 is the hMPV positive control and lane 2--3 are sequence analysis confirmed hMPV positives. Lane 4--10 are aspecific products amplified by the primers.

The inter-run variation for hMPV and hRV in the multiplex PCR was tested amplifying a control (100 TCID~50~) in 10 separate runs. The mean Ct value was 26.0 ± 0.5 and 19.7 ± 0.9 for hRV and hMPV, respectively.

3.2. Testing inhibition using an EAV internal control.
------------------------------------------------------

In this real-time assay an EAV spike was used as an internal control. The EAV dilution used for the spike was 10^4^ plaque forming units/ml with an input of 10 μl per extraction which resulted in a positive result at a Ct value of 33--34. The efficiency of the amplification of dilution series of hRV and hMPV was not significantly affected by co-amplification of EAV in the multiplex reaction ([Table 2](#tbl2){ref-type="table"}). Of the 358 clinical samples tested, 8 (2.2%) were inhibitory and those were five throat washes and three nasal washes.

3.3. Clinical application of the multiplex RNA-PCR
--------------------------------------------------

All 358 specimens collected from 239 patients were cultured to detect common respiratory viruses. None of the specimens were cultured positive for hMPV, probably because the cultures were terminated after 14 days. However, the multiplex PCR revealed that six patients (2.5%) were positive for hMPV. Five patients were children (≤18 years old) and one patient was an adult. Infection with hMPV occurred in five patients in December and in one patient in January. Two patients showed a co-infection of hMPV with RSV. All patients with an hMPV infection were hospitalised with fever and URTI.

Of the 239 patients tested, 41 (17.1%) were positive for hRV in the multiplex RT-PCR and 4 (1.6%) of these were also positive in viral culture. From the 41 patients positive for hRV, 95.2% of the infections were present in children younger than 18 years of age and 4.8% were found in adults. The episodes of hRV positivity detected by PCR per month of the year are shown in [Fig. 2](#fig2){ref-type="fig"} . Infections with hRV were particularly present in the winter months, but also prevalent in summer in immunocompromised patients. Seven patients showed a co-infection with RSV, one with adenovirus and one with PIV1. In two immunocompromised patients, initially an infection with hRV was detected, and at a later time-point an infection with another respiratory virus, RSV and PIV3, respectively. In both cases hRV was detectable for over 4 weeks by the multiplex PCR. The clinical symptoms observed in the hRV positive patients are summarised in [Table 3](#tbl3){ref-type="table"} . Respiratory symptoms were observed in all immunocompetent patients but in the 19 immunocompromised patients 8 had no respiratory symptoms.Fig. 2Cumulative number of episodes of hRV positivity detected by PCR in immunocompromised and immunocompetent patients per month of the year. Immunocompetent patients = ![](fx1.gif) Immunocompromised patients = ![](fx2.gif).Table 3Clinical symptoms in the hRV positive paediatric patientsSymptomImmunocompromised (*n* = 146)Immunocompetent (*n* = 93)URTI1016LRTI1[a](#tbl3fn1){ref-type="table-fn"}4[b](#tbl3fn2){ref-type="table-fn"}Pneumonia00Asthma Exacerbation02No symptoms80  Total1922[^3][^4][^5]

4. Discussion
=============

In order to provide a technique for rapid detection of hRV and hMPV a multiplex RNA PCR was developed with an internal control. These viruses cause a significant number of acute respiratory viral infections in children and are found in more severe respiratory disease as well. The assay was proven to be sensitive with no negative effects by multiplexing. As different probes were used for the two viruses and the internal control, no post PCR analysis was required. The multiplex RT-PCR is specific for hMPV, but the primers and probe designed for hRV also amplify high input concentrations of some enterovirus subtypes with a weak signal. Differentiation between hRV and enteroviruses using hybridisation probes has been described ([@bib10], [@bib9]). Adding a specific EV PCR in the multiplex or sequencing the whole PCR product would solve the problem of differentiation. Unfortunately, no appropriate sequence suitable for real-time PCR and discriminating between hRV and enterovirus subtypes is available ([@bib13]). However, in clinical diagnosis the necessity of further discrimination of hRV and enteroviruses is questionable, as management and therapy issues are not affected by this identification.

The hMPV assays described by van Hoogen et al. have been used in several other studies. ([@bib4], [@bib15], [@bib18], [@bib21]). All these studies have performed RNA-PCR with detection by agarose gel electrophoresis followed by sequencing or hybridisation to confirm an hMPV positive sample. Clearly, the primers for hMPV in the L Gene results in non-specific amplification products on clinical samples ([Fig. 1](#fig1){ref-type="fig"}) but specificity could be obtained using the molecular beacon. Other real-time RT-PCRs have been described for hMPV using the Lightcycler instrument ([@bib4], [@bib11]) but none in an internally controlled multiplex PCR format.

So far, hRV PCR methods have required post-PCR analysis like hybridisation and agarose gel-electrophoresis ([@bib1], [@bib16], [@bib17], [@bib3], [@bib5], [@bib2]) and no real-time PCR methods have been described. Only two multiplex formats have been described with hRV, both of which are nested PCR assays with detection by gel electrophoresis ([@bib2], [@bib7]).

For a real clinical impact for diagnosis of respiratory viruses, other pathogens than hMPV and hRV would have to be included in the assay as well. Previously, a two tube multiplex for influenza A, influenza B, RSV, PIV1--4 was described ([@bib19]). A screening assay for all major respiratory RNA viruses, except for coronaviruses, with results available within one day is possible by combining these assays.

Addition of an internal control reaction is an important requisite for any routine diagnostic PCR assay as each sample is checked for the quality of the nucleic acid extraction and for inhibition. Inhibition was detected in 2.2% of the nasal swabs and throat washes. Although, BALs and sputa are more likely to be inhibitory in this study no inhibition was detected, probably because the limited number of these specimens.

Infection rates for hMPV have ranged from 2% to 35.1% in children ([@bib20], [@bib4], [@bib18], [@bib21]). In this study, the infection in children was 2.2%, which is comparable to the study by Stockton et al. ([@bib18]). One of the reasons for these diverse percentages of hMPV infections is that different clinical criteria were used to select the patients in different studies. In the current study, samples of all patients coming in the hospital with request for respiratory testing were collected, including those of immunocompromised patients, which undergo screening regardless of symptoms. All hMPV infections occurred in the winter-months, which is comparable to what has been found in other studies ([@bib4], [@bib15], [@bib18], [@bib21]). Although all samples were inoculated onto the appropriate cells no hMPV was isolated.

An infection rate of 17.1% hRV was detected in this study and 95% of the hRV infections occurred in children younger than 18 years of age. Only 4 patients were positive for hRV by viral culture, while the multiplex RNA-PCR revealed 41 positive patients. Therefore, viral culture for diagnosis of hRV is very insensitive in this study, but PCR has been shown to be superior for detection of hRV in other studies as well. Molecular methods have demonstrated infection rates as high as 50% in URTI ([@bib17], [@bib3]). In this study, the incidence of hRV infections peaked during the winter, but was also present in autumn and summer in immunocompromised patients.

Co-infections were detected as well; twice hMPV was found together with RSV and six times hRV and RSV were detected. It has been suggested that more severe RSV infection is observed upon co-infection with hMPV ([@bib6]) but with the limited numbers obtained the significance of the co-infection is uncertain. However, in the future these viruses could be routinely detected by using the multiplex assays resulting in further insight into respiratory viral co-infections.

In conclusion, this real-time RNA PCR method enables sensitive diagnosis of hMPV and hRV infections, which are poorly detected by cell culture. This assay can be part of a molecular full respiratory viral screen, thus increasing the understanding of the clinical relevance and epidemiology of these pathogens in respiratory infections.
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[^1]: The stem structure of the molecular beacon is italicised. Reporter dyes: hexachlorofluorescein (HEX); carboxy-fluorescein (FAM); and indodicarbocyanine (Cy5). Quenchers: black hole quencher 1 (BHQ1); dabcyl; and BHQ-2. Probes: molecular beacon (MB); Taqman probe (TQ).

[^2]: For each virus a 10-fold dilution series is shown with Ct values. For each virus the lowest level of detection is shown.

[^3]: URTI was defined as coryza, or rhinorrhea or cough with or without fever but without hypoxia or changes on the chest radiograph. LRTI was defined as signs or symptoms of pulmonary infection such as cough, rales, wheezes, dyspnea or shortness of breath or low oxygen saturation. Pneumonia was defined when in addition to this also abnormalities on chest radiograph (such as infiltrates) were observed.

[^4]: Patient co-infected with CMV.

[^5]: Three patients co-infected with RSV.
